Ad26.ZEBOV is a monovalent vaccine designed to provide active specific acquired immunity to the Ebola virus. The vaccine is based on adenovirus type 26 (Ad26) vector expressing the glycoprotein (GP) of the Ebola virus Mayinga variant.
MVA-BN-Filo is a multivalent vaccine preparation designed to provide active acquired immunity to the Sudan virus, the Ebola virus, the Marburg virus, and the Tai Forest virus (formerly known as Côte d’Ivoire ebolavirus).
These two vaccines combine to make Ad26.ZEBOV/MVA-BN a heterologous prime-boost Ebola vaccine regimen.
These vaccines both use a viral vector approach, where a virus is genetically modified so that it cannot replicate but is used to safely express key proteins of the target virus, in this case, Ebola virus.
Prime-boost vaccination is an established approach for the prevention of other infectious diseases.
These vaccine candidates are administered as an intramuscular (IM) injection.
Clinical Trial: NCT03929757 A Phase 2 Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants
- The purpose of this study is to assess the safety and reactogenicity of a heterologous 2-dose regimen utilizing Ad26.ZEBOV (first vaccination; Dose 1) and MVA-BN-Filo (second vaccination; Dose 2) administered intramuscularly (IM) on Days 1 and 57, respectively.
Clinical Trial: NCT02543567 A Phase 3 Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants